1/5
07:19 am
gyre
Gyre Therapeutics Announces Alignment with China's CDE on Conditional Approval Pathway and Priority Review Eligibility for Hydronidone Following Pre-NDA Meeting [Yahoo! Finance]
High
Report
Gyre Therapeutics Announces Alignment with China's CDE on Conditional Approval Pathway and Priority Review Eligibility for Hydronidone Following Pre-NDA Meeting [Yahoo! Finance]
1/5
07:00 am
gyre
Gyre Therapeutics Announces Alignment with China’s CDE on Conditional Approval Pathway and Priority Review Eligibility for Hydronidone Following Pre-NDA Meeting
High
Report
Gyre Therapeutics Announces Alignment with China’s CDE on Conditional Approval Pathway and Priority Review Eligibility for Hydronidone Following Pre-NDA Meeting
11/18
07:20 am
gyre
Gyre Therapeutics (NASDAQ:GYRE) was upgraded by analysts at Zacks Research from a "strong sell" rating to a "hold" rating.
Medium
Report
Gyre Therapeutics (NASDAQ:GYRE) was upgraded by analysts at Zacks Research from a "strong sell" rating to a "hold" rating.
11/10
06:58 am
gyre
Is Gyre Therapeutics, Inc.'s (NASDAQ:GYRE) ROE Of 8.6% Concerning? [Yahoo! Finance]
Low
Report
Is Gyre Therapeutics, Inc.'s (NASDAQ:GYRE) ROE Of 8.6% Concerning? [Yahoo! Finance]
11/7
06:00 am
gyre
Gyre Therapeutics Reports Third Quarter 2025 and Year-to-Date Financial Results and Provides Business Update
Medium
Report
Gyre Therapeutics Reports Third Quarter 2025 and Year-to-Date Financial Results and Provides Business Update
10/18
07:31 am
gyre
Gyre Therapeutics (NASDAQ:GYRE) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.
Low
Report
Gyre Therapeutics (NASDAQ:GYRE) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.